Waters/$WAT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Waters
Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. In early 2026, Waters merged with Becton Dickinson's life science and diagnostics business, which increased its concentration in diagnostics and discovery-related life science tools.
- Ticker
- $WAT
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 7,900
- Headquarters
- Milford, United States
- Website
- www.waters.com
Waters Metrics
BasicAdvanced
$45B
206.55
$2.21
1.18
-
Price and volume
Market cap
$45B
Beta
1.18
52-week high
$459.63
52-week low
$282.77
Average daily volume
820K
Financial strength
Current ratio
1.861
Quick ratio
1.053
Long term debt to equity
0.343
Total debt to equity
0.335
Interest coverage (TTM)
5.56%
Profitability
EBITDA (TTM)
1,452.048
Gross margin (TTM)
56.34%
Net profit margin (TTM)
3.59%
Operating margin (TTM)
18.06%
Effective tax rate (TTM)
19.06%
Revenue per employee (TTM)
$590,000
Management effectiveness
Return on assets (TTM)
3.56%
Return on equity (TTM)
1.92%
Valuation
Price to earnings (TTM)
206.548
Price to revenue (TTM)
7.367
Price to book
2.96
Price to tangible book (TTM)
-16.36
Price to free cash flow (TTM)
85.791
Free cash flow yield (TTM)
1.17%
Free cash flow per share (TTM)
5.332
Growth
Revenue change (TTM)
52.45%
Earnings per share change (TTM)
-80.02%
3-year revenue growth (CAGR)
15.78%
10-year revenue growth (CAGR)
8.27%
3-year earnings per share growth (CAGR)
-42.00%
10-year earnings per share growth (CAGR)
-9.44%
What the Analysts think about Waters
Analyst ratings (Buy, Hold, Sell) for Waters stock.
Analyst projections of the future price of Waters stock.
Bulls say / Bears say
Waters beat second-quarter revenue and adjusted EPS expectations, with organic sales up 9% in constant currency, and raised its 2026 organic growth and adjusted EPS forecasts. Strength in instruments and recurring chemistry sales suggests demand is broadening beyond a single product line. (Waters, Reuters)
An extended instrument replacement cycle could support sales for several more years: management reported that biotech and contract research customers are beginning to replace equipment, with visibility into demand through 2027. That could add to recurring service and consumables revenue as instruments return to use. (StockAnalysis)
Waters’ new AI Link connects laboratory software with AI agents that can direct instruments and automate experiments. If labs adopt these workflows, more AI-designed tests could drive demand for Waters’ instruments and consumables. (Waters)
The BD acquisition has left Waters with $5.1 billion of outstanding debt, adding interest and repayment obligations as it integrates the acquired business. Higher financing costs could limit the cash available for investment or shareholder returns. (SEC)
Acquisition accounting made second-quarter GAAP results a $1.39 per-share loss, even as adjusted EPS was $3.05, due largely to acquired-intangible amortisation and inventory step-up charges. The gap makes reported earnings harder to assess and may persist while these charges run through results. (Waters)
The acquired Biosciences and Diagnostics businesses grew only 4% in the second quarter, and China remained a drag, including a 20% decline in flow clinical revenue. This leaves Waters needing to sustain its turnaround and localise products before the enlarged portfolio can deliver stronger growth. (MarketBeat, Waters)
Data summarised monthly by Lightyear AI. Last updated on 17 Oct 2026.
Waters Financial Performance
Revenues and expenses
Waters Earnings Performance
Company profitability
Upcoming events
No upcoming events
Waters News
AllArticlesVideos
Two stocks poised to benefit from rotation out of AI
Invezz3 days ago
Waters Tops Growth Outlook as AI Demand, BD Integration Fuel Momentum
MarketBeat4 weeks ago
Everlywell Announces a Partnership with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients
Business Wire1 month ago
Funds containing Waters
AllUSDEURGBP
Fund name | Fund size | $WAT weighting |
|---|---|---|
iShares MSCI World Health Care Sector Advanced£WHCA | $362M | 0.82% |
iShares MSCI World Health Care Sector Advanced€CBUF | $683M | 0.82% |
Invesco Health Care S&P US Select Sector£XLVP | $552M | 0.70% |
Invesco Health Care S&P US Select Sector$XLVS | $552M | 0.70% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 0.67% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.